B Group, Inc.: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 2043476) · Explore on the interactive board
B Group, Inc. disclosed 18 US equity positions worth $176.2m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is ADMA at 15.5% of the reported book, followed by PALI, NRXP. The top ten holdings are 79.2% of the book, and the portfolio behaves like about 12 equal-weight positions. Versus the prior filing it opened 1 new position, added to 5, reduced 1 and exited 3. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does B Group, Inc. own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 1 new, 5 added, 1 reduced, 3 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | ADMA ADMA BIOLOGICS INC | Healthcare | 15.5% | $27.3m | 3,262,542 | 2% | added |
| 2 | PALI PALISADE BIO INC | Healthcare | 13.5% | $23.9m | 11,414,285 | 0% | held |
| 3 | NRXP NRX PHARMACEUTICALS INC | 9.5% | $16.7m | 4,091,767 | 36% | added | |
| 4 | FTH FAETH THERAPEUTICS INC | 8.7% | $15.3m | 610,169 | – | new | |
| 5 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 7.0% | $12.3m | 1,800,556 | 0% | held |
| 6 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 6.3% | $11.1m | 33,237 | 0% | held |
| 7 | CLLS CELLECTIS S A | 5.6% | $9.8m | 3,281,501 | 0% | held | |
| 8 | ZLAB ZAI LAB LTD | Healthcare | 4.9% | $8.6m | 450,646 | 0% | held |
| 9 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 4.3% | $7.5m | 140,000 | 10% | added |
| 10 | ORKA ORUKA THERAPEUTICS INC | Healthcare | 4.1% | $7.1m | 75,000 | 0% | held |
| 11 | IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 3.5% | $6.2m | 1,500,000 | 0% | held |
| 12 | SYRE SPYRE THERAPEUTICS INC | Healthcare | 3.5% | $6.2m | 70,000 | -30% | reduced |
| 13 | AURA AURA BIOSCIENCES INC | 3.1% | $5.4m | 764,243 | 28% | added | |
| 14 | ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 2.7% | $4.8m | 175,706 | 0% | held |
| 15 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 2.7% | $4.7m | 67,500 | 0% | held |
| 16 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 2.6% | $4.5m | 135,000 | 0% | held |
| 17 | SGHT SIGHT SCIENCES INC | 2.1% | $3.7m | 970,000 | 0% | held | |
| 18 | FHTX FOGHORN THERAPEUTICS INC | Healthcare | 0.6% | $976.0k | 200,000 | 96% | added |
What did B Group, Inc. sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| APGE APOGEE THERAPEUTICS INC | 58.4% | $631.3k |
| SLNOEUR SOLENO THERAPEUTICS INC | 23.2% | $251.1k |
| REPL REPLIMUNE GROUP INC | 18.4% | $198.9k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 71.1% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is B Group, Inc.'s portfolio?
Across every quarter B Group, Inc. has filed, its median largest position is 18.5% of the book and its median top-ten weight is 80.2%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 3.0 completed holding spells, the median lasted 1.0 quarters; 18.0 positions are still open and their final length is unknown.